Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEL114674: 2-year study of efficacy and safety of belimumab in idiopathic membranous nephropathy
2011-000242-38Phase 2Terminated
- Sponsor
- GSK
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belimumab in idiopathic membranous glomerulonephritis (IMG) and membranous glomerulonephritis (MGN), sponsored by GSK. Primary endpoint: Incidence of remission (complete or partial) at Week 104. Started Sep 2012; status: terminated.
02
Drugs
belimumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2011-000242-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000242-38.